January 2017, FDA released the FDA Compounding Progress Report which summarizes FDA activity in the compounding space in the 3 years following passage of the Drug Quality and Security Act. A PDF version of the report is available here.
A few highlights as of Nov 27, 2016 FDA has (p.10):
On page 12, the FDA identified continued concern about the risk to patients from compounded drugs. Many non outsourcing registered facilities were engaged in large-scale manufacturing.
Additionally FDA continues to identify insanitary conditions in many of the facilities inspected. Pictures in the report identified a few of the conditions encountered during inspection. One example provided from the report (left) identifies mold on ceiling tiles of a compounding facility.
Lastly several examples were provided of serious adverse events and product quality related issues of both sterile and non-sterile products including:
Drugs compounded under 503A and B serve a recognized and important need for patients. However, these drugs need to meet appropriate quality standards to prevent patient harm. FDA is committed to provide appropriate oversight to protect public health.